Clinical trial
Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
NCT00446368 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
- Lead sponsor
- The Methodist Hospital Research Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2005
- Completion date
- October 31, 2008
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.